Pharmaceuticals and Life Sciences Publications

• Diagnostics 2011:
  M&A surges, companion diagnostics accelerate, and early detection offers new prospects

PwC’s Diagnostics 2011 provides an overview of M&A deal activity during the past two years and the factors driving it, the development of new prospects for early detection testing and a review of significant events for the development of personalised medicine. The report also includes an in-depth discussion about trends in companion diagnostics and business model considerations for pharmaceutical companies.

• Executive summary

• Regional Biotechnology

Establishing a methodology and performance indicators for assessing bioclusters and bioregions relevant to the Knowledge-based Bio-economy in Europe.

• eHealth Service Platform Study

This report describes opportunities to implement an interoperability platform for electronic health services in Luxembourg. It also provides recommendations for this platform as well as for related preliminary decisions to be taken such as the setup of a dedicated agency.

For more information click here.

• Diagnostics 2009: Moving towards personalised medicine

The fabric of the in vitro diagnostics (IVD) industry is changing. New names are appearing at the top and some emerging specialists are being valued more than some traditional big names: Siemens and Inverness entered the ranks of the top ten by sales after a flurry of deals in 2006-2007, and the women’s healthcare specialist, Hologic, increased its value through key combinations in 2007-2008.
In this new report, PricewaterhouseCoopers reviews deal activity in the in vitro diagnostics (IVD) sector and significant events for personalised medicine, a field which is fast rising to prominence in healthcare innovation.
The report covers: M&A and licensing deal activity; Biomarkers and companion diagnostics; Partnerships with the pharmaceutical industry; Significant events for personalised medicine; Case studies; Drivers of future revenue growth for personalised medicine.